Urinary Bladder, Overactive

PARK CITY, Utah--(BUSINESS WIRE)--BlueWind Medical, Ltd., a leader in implantable Tibial NeuroModulation (iTNM) and developer of the Revi® System, a patient-centric tibial neuromodulation solution for urgency urinary incontinence (UUI), announced today 24-month Quality of Life (QoL) results from the OASIS pivotal study showing sustained and clinically meaningful improvements. The research was presented at the annual meeting of the American Urological Association (AUA) in Las Vegas. UUI is commonly associated with decreased quality of life, an important metric that supports comprehensive quality of clinical care for patients.1 The OASIS trial showed that Revi demonstrated consistent QoL benefits throughout 24 months, with clinically significant (≥10-point change) and sustainable improvements in symptom severity in all domains of the Overactive Bladder Questionnaire (OAB-q), including coping, concern, sleep and social, and a total transformed Health-Related QoL (HRQL) score of (87.2%). Symptom severity (transformed score), saw highly impactful improvement with a nearly 40-point reduction, from 70.3 to 32.4, 30.6, and 31.5 at six months, 12 months, and 24 months, respectively, Additional study highlights: As previously reported, primary efficacy and safety endpoints were met with a UUI response rate of 79.4% (≥50% decrease in UUI) and no device- or procedure-related serious adverse events. At 24 months, 96.8% reported treatment benefit, 96.7% reported satisfaction, and 100% reported a willingness to continue therapy. Importantly, even in participants who did not meet the efficacy endpoint at 24 months (21%), appreciable therapeutic benefit was still noted; in patients with large leaks within this subgroup, 58.8% reported no large leaks in their 24-month voiding diaries. Additionally, 83.3% reported treatment benefit, 66.7% reported satisfaction, and 100.0% reported a willingness to continue Revi therapy. The OASIS study demonstrates that iTNM with Revi represents a highly effective treatment modality for UUI that results in clinically meaningful and sustainable improvements in both bladder-related and overall health-related QoL. These important QoL improvements were seen within six months of implant activation and were sustained through 24 months. “OASIS findings presented today continue to underscore the strength of Revi's efficacy alongside improvements in quality of life for people living with disruptive UUI,” said Roger Dmochowski, M.D., Chief Medical Advisor, BlueWind Medical, who presented the research findings. “UUI can derail active and full lives and is often associated with significant distress. The data presented today builds on an extensive body of evidence supporting Revi as an intervention that restores quality of life for many patients.” About Urge Urinary Incontinence (UUI) and Quality of Life UUI, also known as Urgency Urinary Incontinence, is a chronic condition, which means it won’t go away by itself. It can be a disabling condition with physical, psychological, and social consequences that may significantly impact quality of life.1 UUI is associated with a high negative impact on patient’s quality of life, including causing people with symptoms to stay at home, decreasing physical activities and attributing weight gain to an inability to exercise. Women are significantly more likely to report disturbed sleep, decreased self-esteem, decreased sexuality, and feelings of overall declining health related to UUI.2 About the OASIS Study The OASIS (Overactive Bladder Stimulation System Study) trial is a prospective, multicenter, single-arm, open-label clinical study of 151 adult women (mean age 58.8 years) with UUI (urgency urinary incontinence; overactive bladder-wet syndrome [OAB-wet]). The trial evaluated the efficacy and safety of Revi in treating UUI symptoms in patients with OAB-wet. Primary efficacy and safety endpoints were assessed at six and 12 months, with 97 participants completing the 24-month assessment. Revi is the first iTNM device for the treatment of UUI labeled for use without prior failure of more conservative therapies, including medication. With concerns3 about the potential link between anticholinergic agents and dementia risk, there is an increased need for flexible, non-pharmacologic treatment options. For more information on BlueWind Medical and the Revi System, please visit bluewindmedical.com. About BlueWind Medical Ltd. BlueWind Medical is transforming the field of neuromodulation therapy through the development of innovative, patient-centric medical technology for the treatment of disease. BlueWind is committed to enhancing the quality of life and overall well-being of patients with an initial focus on those living with urge urinary incontinence (UUI). BlueWind’s Revi® System is the first and only implantable tibial neuromodulation device activated by a battery-operated external wearable to receive FDA clearance for patients with UUI. Revi is the only neuromodulation therapy on the market that allows physicians to use their discretion to determine whether the patient should fail or not tolerate more conservative treatments before using the Revi System rather than mandating “step-therapy.” For additional information about BlueWind Medical, please visit bluewindmedical.com. References Pizzol, D. et. al. Urinary incontinence and quality of life: a systematic review and meta analysis. Aging Clinical and Experimental Research . 2021; 33:25-35. https://doi-org.libproxy1.nus.edu.sg/10.1007/s40520-020-01712-y Reynolds, W.S. et. al. The Burden of Overactive Bladder on US Public Health. Current Bladder Dysfunction Reports. 2016; 11(1), 8-13. https://doi-org.libproxy1.nus.edu.sg/10.1007/s11884-016-0344-9 Coupland, Carol et. al. Anticholinergic Drug Exposure and the Risk of Dementia. JAMA Intern Med. 2019;179(8):1084-1093. doi:10.1001/jamainternmed.2019.0677

– Data include results from COURAGE Phase 3 and COMPOSUR Phase 4 studies of vibegron (GEMTESA®) – MARLBOROUGH, Mass., April 29, 2025 /PRNewswire/ -- Sumitomo Pharma America, Inc. (SMPA) presented new, positive data from the COURAGE Phase 3 open-label extension study of vibegron (GEMTESA®) in men living with overactive bladder (OAB) and receiving pharmacological therapy for benign prostatic hyperplasia (BPH). Data presented from the Phase 3 COURAGE trial (URO-901-3006) included a total of 276 men with OAB symptoms receiving pharmacological therapy for BPH who participated in the open-label extension study. The primary outcome was to evaluate the long-term safety of vibegron 75 mg, which was well tolerated for up to 52 weeks in men with symptoms of OAB who were receiving pharmacological treatment for BPH. The data reveal that the efficacy results of treatment with vibegron 75 mg a day were sustained among those receiving vibegron for 52 weeks and improved after 28 weeks of vibegron treatment for those who received placebo during the first 12 weeks of a double-blind placebo-controlled study (URO-901-3005). Sustained efficacy results in all secondary outcomes were observed, including mean daily micturitions, urgency episodes, nocturia episodes, urge urinary incontinence episodes, IPSS-Storage and volume voided per micturition. Vibegron demonstrated favorable long-term safety and efficacy, with no new safety signals compared to prior OAB studies. At the conference SMPA also shared findings from the Phase 4 COMPOSUR, real-world study of vibegron in patients with OAB, which continue to support that it was generally safe and well-tolerated, with the majority of patients satisfied with treatment and remaining on vibegron after 12 months. Most common adverse events were urinary tract infection (4.0%), headache (2.7%), dizziness (2.2%) and diarrhea (2.0%). "SMPA remains committed to advancing scientific innovation that helps the lives of the millions of patients suffering from OAB and receiving pharmacological therapy for BPH," said Tsutomu Nakagawa, Ph.D., President and Chief Executive Officer of SMPA. "These data continue to reaffirm vibegron's safety and tolerability." Vibegron is approved for OAB with symptoms of urge urinary incontinence, urgency and urinary frequency in adults, and in December 2024, became the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS GEMTESA is contraindicated in patients with known hypersensitivity to vibegron or any components of GEMTESA. Hypersensitivity reactions, such as angioedema, have occurred. WARNINGS AND PRECAUTIONS Urinary Retention Urinary retention has been reported in patients taking GEMTESA. The risk of urinary retention may be increased in patients with bladder outlet obstruction and also in patients taking muscarinic antagonist medications for the treatment of OAB. Monitor patients for signs and symptoms of urinary retention, particularly in patients with bladder outlet obstruction or patients taking muscarinic antagonist medications for the treatment of OAB. Discontinue GEMTESA in patients who develop urinary retention. Angioedema Angioedema of the face and/or larynx has been reported with GEMTESA. Angioedema has been reported to occur hours after the first dose or after multiple doses. Angioedema, associated with upper airway swelling, may be life-threatening. If involvement of the tongue, hypopharynx, or larynx occurs, immediately discontinue GEMTESA and provide appropriate therapy and/or measures necessary to ensure a patent airway. ADVERSE REACTIONS Most common adverse reactions (≥2%) reported with GEMTESA were headache, urinary tract infection, nasopharyngitis, diarrhea, nausea, and upper respiratory tract infection. INDICATIONS AND USAGE GEMTESA® is a beta-3 adrenergic agonist indicated for the treatment of: overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults. overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adult males on pharmacological therapy for benign prostatic hyperplasia (BPH). Please click here for full Prescribing Information. About GEMTESA® (vibegron) In the U.S., GEMTESA (vibegron) has been indicated for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults since April 2021. GEMTESA was approved on December 18, 2024, for overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adult males on pharmacological therapy for benign prostatic hyperplasia (BPH). GEMTESA works by selectively targeting β3 adrenergic receptors to reduce OAB symptoms through the relaxation of the bladder detrusor muscle to increase capacity. About Overactive Bladder Overactive bladder (OAB) is a clinical condition that occurs when the bladder muscle contracts involuntarily. Symptoms may include urinary urgency (the sudden urge to urinate that is difficult to control), urgency incontinence (unintentional loss of urine immediately after an urgent need to urinate), and frequent urination (usually eight or more times in 24 hours).7 Approximately 33 million U.S. adults experience the bothersome symptoms of OAB.1 About Benign Prostatic Hyperplasia Benign prostatic hyperplasia (BPH) is a condition in men in which the prostate gland is enlarged. Many men who are treated for symptoms are assumed to have an obstruction in the bladder caused by an enlarged prostate.4, 5 Even when the obstruction is alleviated by BPH treatment, unresolved symptoms of OAB may persist. About 60% of men with BPH are treated for lower urinary tract symptoms (LUTS).4, 5 LUTS can be divided into storage, voiding, and postmicturition symptoms.8 More than half of men with LUTS report storage symptoms, and about a quarter report voiding symptoms.5 This suggests that many men with a diagnosis of BPH may have overactive bladder.5 About Sumitomo Pharma Sumitomo Pharma Co., Ltd., is a global pharmaceutical company based in Japan with key operations in the U.S. (Sumitomo Pharma America, Inc.), Canada (Sumitomo Pharma Canada, Inc.), and Europe (Sumitomo Pharma Switzerland GmbH) focused on addressing patient needs in oncology, urology, women's health, rare diseases, psychiatry & neurology, and cell & gene therapies. With several marketed products in the U.S., Canada, and Europe, a diverse pipeline of early- to late-stage assets, we aim to accelerate discovery, research, and development to bring novel therapies to patients sooner. For more information on SMPA, visit our website or follow us on LinkedIn. The Sumitomo corporate symbol mark is a trademark of Sumitomo Pharma Co., Ltd., used under license. SUMITOMO PHARMA is a trademark of Sumitomo Pharma Co., Ltd., used under license. SUMITOMO is a registered trademark of Sumitomo Chemical Co., Ltd., used under license. Sumitomo Pharma America, Inc. is a U.S. subsidiary of Sumitomo Pharma Co., Ltd. GEMTESA, and the GEMTESA logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries. ©2025 Sumitomo Pharma America, Inc. All rights reserved. References Gomelsky A, Dmochowski RR. Update on the management of overactive bladder: patient considerations and adherence. Open Access J Urol. 2011;3:7-17. doi:10.2147/OAJU.S7233 Deters LA. Benign Prostatic Hyperplasia (BPH). . Updated March 22, 2023. Accessed December 18, 2024 Gomelsky A, Dmochowski RR. Overactive bladder in males. Ther Adv Urol. 2009;1(4):209-221. doi:10.1177/1756287209350383 Burnett AL, Walker DR, Feng Q, et al. Undertreatment of overactive bladder among men with lower urinary tract symptoms in the United States: a retrospective observational study. Neurourol Urodyn. 2020;39(5):1378-1386. doi:10.1002/nau.24348 Anger JT, Goldman HB, Luo X, et al. Patterns of medical management of overactive bladder (OAB) and benign prostatic hyperplasia (BPH) in the United States. Neurourol Urodyn. 2018;37(1):213-222. doi:10.1002/nau.23276 GEMTESA. Prescribing Information. Marlborough, MA; Sumitomo Pharma America; 2024 Overactive bladder – symptoms and causes. Mayo Clinic. March 2 2024. Accessed December 18, 2024. Lepor H. Pathophysiology of lower urinary tract symptoms in the aging male population. Rev Urol. 2005;7 suppl 7(suppl 7):S3-S11. PMID: 16986059; PMCID: PMC1477625. SOURCE Sumitomo Pharma America WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

MONDAY, April 7, 2025 -- The Geriatric Nutritional Risk Index (GNRI) is a reliable predictive marker for overactive bladder (OAB) in the elderly, according to a study published online Feb. 10 in Frontiers in Nutrition . Wei Zheng, from Hangzhou Medical College in China, and colleagues examined the association between GNRI and the prevalence of OAB in a study involving 17,161 elderly individuals from the National Health and Nutrition Examination Survey between 2005 and 2018. Subgroup analyses were used to assess influencing factors, and the predictive utility of GNRI was examined. A mediation analysis was conducted to assess the influence of inflammatory response and cognitive function on the interaction between GNRI and OAB. The researchers found that GNRI was significantly lower in the OAB group versus the non-OAB group. GNRI significantly predicted OAB in a multifactorial logistic regression analysis. A nonlinear negative correlation was seen between GNRI and the risk for OAB in the elderly. GNRI outperformed serum albumin or body mass index alone in predicting OAB risk in a receiver operating characteristic analysis. The relationship between GNRI and OAB was mediated by inflammatory response, while a relatively weaker influence on the strength of the association between GNRI and OAB was seen for cognitive function. "From a clinical perspective, GNRI can be incorporated into routine screening to enhance risk stratification and inform personalized treatment strategies, potentially improving outcomes for OAB patients or those at risk of OAB," the authors write Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.